Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with Osteoporosis
Robert M. Neer, Claude D. Arnaud, Jose R. Zanchetta, Richard Prince, Gregory A. Gaich, Jean-Yves Reginster, Anthony B. Hodsman, Erik F. Eriksen, Sophia Ish-Shalom, Harry K. Genant, Ouhong Wang, Bruce H. Mitlak, Dan Mellstrom, Erik S. Oefjord, Ewa Marcinowska-Suchowierska, Jorma Salmi, Henk Mulder, Johan Halse, and Andrzej Z. Sawicki
Background Once-daily injections of parathyroid hormone or itsamino-terminal fragments increase bone formation and bone masswithout causing hypercalcemia, but their effects on fracturesare unknown.
Methods We randomly assigned 1637 postmenopausal women withprior vertebral fractures to receive 20 or 40 µg of parathyroidhormone (1-34) or placebo, administered subcutaneously by thewomen daily. We obtained vertebral radiographs at base lineand at the end of the study (median duration of observation,21 months) and performed serial measurements of bone mass bydual-energy x-ray absorptiometry.
Results New vertebral fractures occurred in 14 percent of thewomen in the placebo group and in 5 percent and 4 percent, respectively,of the women in the 20-µg and 40-µg parathyroidhormone groups; the respective relative risks of fracture inthe 20-µg and 40-µg groups, as compared with theplacebo group, were 0.35 and 0.31 (95 percent confidence intervals,0.22 to 0.55 and 0.19 to 0.50). New nonvertebral fragility fracturesoccurred in 6 percent of the women in the placebo group andin 3 percent of those in each parathyroid hormone group (relativerisk, 0.47 and 0.46, respectively [95 percent confidence intervals,0.25 to 0.88 and 0.25 to 0.86]). As compared with placebo, the20-µg and 40-µg doses of parathyroid hormone increasedbone mineral density by 9 and 13 more percentage points in thelumbar spine and by 3 and 6 more percentage points in the femoralneck; the 40-µg dose decreased bone mineral density atthe shaft of the radius by 2 more percentage points. Both dosesincreased total-body bone mineral by 2 to 4 more percentagepoints than did placebo. Parathyroid hormone had only minorside effects (occasional nausea and headache).
Conclusions Treatment of postmenopausal osteoporosis with parathyroidhormone (1-34) decreases the risk of vertebral and nonvertebralfractures; increases vertebral, femoral, and total-body bonemineral density; and is well tolerated. The 40-µg doseincreased bone mineral density more than the 20-µg dosebut had similar effects on the risk of fracture and was morelikely to have side effects.
Source Information
From Massachusetts General Hospital and Harvard Medical School, Boston (R.M.N.); the University of California, San Francisco (C.D.A., H.K.G.); Fundación de Investigaciones Metabólicas, Buenos Aires, Argentina (J.R.Z.); the University of Western Australia and Sir Charles Gairdner Hospital, Perth, Australia (R.P.); Eli Lilly, Indianapolis (G.A.G., O.W., B.H.M.); Polycliniques Universitaires L. Brull, Liege, Belgium (J.-Y.R.); St. Joseph's Health Center, London, Ont., Canada (A.B.H.); Aarhus Amtssygehus, Aarhus, Denmark (E.F.E.); and Rambam Medical Center, Haifa, Israel (S.I.-S.).
Other authors were Dan Mellström, Department of Geriatrics, University of Göteborg, Göteborg, Sweden; Erik S. Oefjord, Bergen Osteoporosesenter, Paradis, Norway; Ewa Marcinowska-Suchowierska, Klinika Chorob Wewnetrznych, Warsaw, Poland; Jorma Salmi, Koskiklinikka, Tampere, Finland; Henk Mulder, Medisch Onderzoekscentrum Gcp, De Bilt, the Netherlands; Johan Halse, Betanien Med Lab, Oslo, Norway; and Andrzej Z. Sawicki, Warszawskie Centrum Osteoporozy, Warsaw, Poland.
Address reprint requests to Dr. Mitlak at Eli Lilly, Inc., Lilly Corporate Center, Indianapolis, IN 46285-2680, or at b.mitlak{at}lilly.com.
Ono, N., Nakashima, K., Rittling, S. R., Schipani, E., Hayata, T., Soma, K., Denhardt, D. T., Kronenberg, H. M., Ezura, Y., Noda, M.
(2008). Osteopontin Negatively Regulates Parathyroid Hormone Receptor Signaling in Osteoblasts. J. Biol. Chem.
283: 19400-19409
[Abstract][Full Text]
Ishani, A., Blackwell, T., Jamal, S. A., Cummings, S. R., Ensrud, K. E., for the MORE Investigators,
(2008). The Effect of Raloxifene Treatment in Postmenopausal Women with CKD. J. Am. Soc. Nephrol.
19: 1430-1438
[Full Text]
Nemeth, E. F.
(2008). Anabolic Therapy for Osteoporosis: Calcilytics. IBMS BoneKEy
5: 196-208
[Abstract][Full Text]
Nielsen, D., Ryg, J., Nissen, N., Nielsen, W., Knold, B., Brixen, K.
(2008). Multidisciplinary patient education in groups increases knowledge on osteoporosis: A randomized controlled trial. Scand J Public Health
36: 346-352
[Abstract]
Gehrig, L., Lane, J., O'Connor, M. I.
(2008). Osteoporosis: Management and Treatment Strategies for Orthopaedic Surgeons. JBJS
90: 1362-1374
[Full Text]
Black, D. M., Bouxsein, M. L., Palermo, L., McGowan, J. A., Newitt, D. C., Rosen, E., Majumdar, S., Rosen, C. J., for the PTH Once-Weekly Research (POWR) Group,
(2008). Randomized Trial of Once-Weekly Parathyroid Hormone (1-84) on Bone Mineral Density and Remodeling. J. Clin. Endocrinol. Metab.
93: 2166-2172
[Abstract][Full Text]
Cole, Z., Dennison, E., Cooper, C.
(2008). Update on the treatment of post-menopausal osteoporosis. Br Med Bull
86: 129-143
[Abstract][Full Text]
Pearsall, R. S., Canalis, E., Cornwall-Brady, M., Underwood, K. W., Haigis, B., Ucran, J., Kumar, R., Pobre, E., Grinberg, A., Werner, E. D., Glatt, V., Stadmeyer, L., Smith, D., Seehra, J., Bouxsein, M. L.
(2008). A soluble activin Type IIA receptor induces bone formation and improves skeletal integrity. Proc. Natl. Acad. Sci. USA
105: 7082-7087
[Abstract][Full Text]
Grundberg, E., Brandstrom, H., Lam, K. C. L., Gurd, S., Ge, B., Harmsen, E., Kindmark, A., Ljunggren, O., Mallmin, H., Nilsson, O., Pastinen, T.
(2008). Systematic assessment of the human osteoblast transcriptome in resting and induced primary cells. Physiol. Genomics
33: 301-311
[Abstract][Full Text]
Liu, H., Paige, N. M., Goldzweig, C. L., Wong, E., Zhou, A., Suttorp, M. J., Munjas, B., Orwoll, E., Shekelle, P.
(2008). Screening for Osteoporosis in Men: A Systematic Review for an American College of Physicians Guideline. ANN INTERN MED
148: 685-701
[Abstract][Full Text]
Edwards, B. J., Migliorati, C. A.
(2008). Osteoporosis and Its Implications for Dental Patients. Journal of the American Dental Association
139: 545-552
[Abstract][Full Text]
Rozental, T. D., Makhni, E. C., Day, C. S., Bouxsein, M. L.
(2008). Improving Evaluation and Treatment for Osteoporosis Following Distal Radial Fractures. A Prospective Randomized Intervention. JBJS
90: 953-961
[Abstract][Full Text]
Yu, S., Franceschi, R. T., Luo, M., Zhang, X., Jiang, D., Lai, Y., Jiang, Y., Zhang, J., Xiao, G.
(2008). Parathyroid Hormone Increases Activating Transcription Factor 4 Expression and Activity in Osteoblasts: Requirement for Osteocalcin Gene Expression. Endocrinology
149: 1960-1968
[Abstract][Full Text]
Pioszak, A. A., Xu, H. E.
(2008). Molecular recognition of parathyroid hormone by its G protein-coupled receptor. Proc. Natl. Acad. Sci. USA
105: 5034-5039
[Abstract][Full Text]
Stroup, J., Kane, M. P., Abu-Baker, A. M.
(2008). Teriparatide in the treatment of osteoporosis. Am J Health Syst Pharm
65: 532-539
[Abstract][Full Text]
Anastasilakis, A. D, Goulis, D. G, Polyzos, S. A, Gerou, S., Pavlidou, V., Koukoulis, G., Avramidis, A.
(2008). Acute changes in serum osteoprotegerin and receptor activator for nuclear factor-{kappa}B ligand levels in women with established osteoporosis treated with teriparatide. Eur J Endocrinol
158: 411-415
[Abstract][Full Text]
Boonen, S., Marin, F., Obermayer-Pietsch, B., Simoes, M. E., Barker, C., Glass, E. V., Hadji, P., Lyritis, G., Oertel, H., Nickelsen, T., McCloskey, E. V., for the EUROFORS Investigators,
(2008). Effects of Previous Antiresorptive Therapy on the Bone Mineral Density Response to Two Years of Teriparatide Treatment in Postmenopausal Women with Osteoporosis. J. Clin. Endocrinol. Metab.
93: 852-860
[Abstract][Full Text]
Lloyd, S. A.J., Travis, N. D., Lu, T., Bateman, T. A.
(2008). Development of a low-dose anti-resorptive drug regimen reveals synergistic suppression of bone formation when coupled with disuse. J. Appl. Physiol.
104: 729-738
[Abstract][Full Text]
MacLaughlin, E. J., Raehl, C. L.
(2008). ASHP Therapeutic Position Statement on the Prevention and Treatment of Osteoporosis in Adults. Am J Health Syst Pharm
65: 343-357
[Full Text]
MacLean, C., Newberry, S., Maglione, M., McMahon, M., Ranganath, V., Suttorp, M., Mojica, W., Timmer, M., Alexander, A., McNamara, M., Desai, S. B., Zhou, A., Chen, S., Carter, J., Tringale, C., Valentine, D., Johnsen, B., Grossman, J.
(2008). Systematic Review: Comparative Effectiveness of Treatments to Prevent Fractures in Men and Women with Low Bone Density or Osteoporosis. ANN INTERN MED
148: 197-213
[Abstract][Full Text]
Kunzendorf, U., Kramer, B. K., Arns, W., Braun, J., Grossmann, J., Pietruck, F., Schmidt-Gayk, H., Schwarz, A., Ziegler, E., Sperschneider, H., Wuthrich, R. P., Nonnast-Daniel, B., Schindler, R., Renders, L.
(2008). Bone disease after renal transplantation. Nephrol Dial Transplant
23: 450-458
[Full Text]
Barnes, G. L., Kakar, S., Vora, S., Morgan, E. F., Gerstenfeld, L. C., Einhorn, T. A.
(2008). Stimulation of Fracture-Healing with Systemic Intermittent Parathyroid Hormone Treatment. JBJS
90: 120-127
[Abstract][Full Text]
Garnero, P., Vergnaud, P., Hoyle, N.
(2008). Evaluation of a Fully Automated Serum Assay for Total N-Terminal Propeptide of Type I Collagen in Postmenopausal Osteoporosis. Clin. Chem.
54: 188-196
[Abstract][Full Text]
Dawson-Hughes, B., Chen, P., Krege, J. H.
(2007). Response to Teriparatide in Patients with Baseline 25-Hydroxyvitamin D Insufficiency or Sufficiency. J. Clin. Endocrinol. Metab.
92: 4630-4636
[Abstract][Full Text]
Saag, K. G., Shane, E., Boonen, S., Marin, F., Donley, D. W., Taylor, K. A., Dalsky, G. P., Marcus, R.
(2007). Teriparatide or Alendronate in Glucocorticoid-Induced Osteoporosis. NEJM
357: 2028-2039
[Abstract][Full Text]
Li, X., Qin, L., Bergenstock, M., Bevelock, L. M., Novack, D. V., Partridge, N. C.
(2007). Parathyroid Hormone Stimulates Osteoblastic Expression of MCP-1 to Recruit and Increase the Fusion of Pre/Osteoclasts. J. Biol. Chem.
282: 33098-33106
[Abstract][Full Text]
POTTS, J. T., GARDELLA, T. J.
(2007). Progress, Paradox, and Potential: Parathyroid Hormone Research over Five Decades. Ann. N. Y. Acad. Sci.
1117: 196-208
[Abstract][Full Text]
Tylavsky, F. A., Ryder, K. M., Li, R., Park, V., Womack, C., Norwood, J., Carbone, L. D., Cheng, S.
(2007). Preliminary Findings: 25(OH)D Levels and PTH Are Indicators of Rapid Bone Accrual in Pubertal Children. J. Am. Coll. Nutr.
26: 462-470
[Abstract][Full Text]
Lee, S. H., Gupta, M. K., Han, D. W., Han, S. Y., Uhm, S. J., Kim, T., Lee, H. T.
(2007). Development of Transgenic Chickens Expressing Human Parathormone Under the Control of a Ubiquitous Promoter by Using a Retrovirus Vector System. Poult. Sci.
86: 2221-2227
[Abstract][Full Text]
Miller, P. D., Bilezikian, J. P., Diaz-Curiel, M., Chen, P., Marin, F., Krege, J. H., Wong, M., Marcus, R.
(2007). Occurrence of Hypercalciuria in Patients with Osteoporosis Treated with Teriparatide. J. Clin. Endocrinol. Metab.
92: 3535-3541
[Abstract][Full Text]
Johnston, S., Andrews, S., Shen, V., Cosman, F., Lindsay, R., Dempster, D. W., Iida-Klein, A.
(2007). The Effects of Combination of Alendronate and Human Parathyroid Hormone(1 34) on Bone Strength Are Synergistic in the Lumbar Vertebra and Additive in the Femur of C57BL/6J Mice. Endocrinology
148: 4466-4474
[Abstract][Full Text]
Canalis, E., Giustina, A., Bilezikian, J. P.
(2007). Mechanisms of Anabolic Therapies for Osteoporosis. NEJM
357: 905-916
[Full Text]
Bruyere, O., Roux, C., Detilleux, J., Slosman, D. O., Spector, T. D., Fardellone, P., Brixen, K., Devogelaer, J.-P., Diaz-Curiel, M., Albanese, C., Kaufman, J.-M., Pors-Nielsen, S., Reginster, J.-Y.
(2007). Relationship between Bone Mineral Density Changes and Fracture Risk Reduction in Patients Treated with Strontium Ranelate. J. Clin. Endocrinol. Metab.
92: 3076-3081
[Abstract][Full Text]
Blake, G. M, Fogelman, I.
(2007). The role of DXA bone density scans in the diagnosis and treatment of osteoporosis. Postgrad. Med. J.
83: 509-517
[Abstract][Full Text]
Su, J.-L., Yang, C.-Y., Zhao, M., Kuo, M.-L., Yen, M.-L.
(2007). Forkhead Proteins Are Critical for Bone Morphogenetic Protein-2 Regulation and Anti-tumor Activity of Resveratrol. J. Biol. Chem.
282: 19385-19398
[Abstract][Full Text]
Roux, C., Briot, K., Horlait, S., Varbanov, A., Watts, N. B, Boonen, S.
(2007). Assessment of non-vertebral fracture risk in postmenopausal women. Ann Rheum Dis
66: 931-935
[Abstract][Full Text]
Kingsley, L. A., Chirgwin, J. M., Guise, T. A.
(2007). Breaking new ground to build bone. Proc. Natl. Acad. Sci. USA
104: 10753-10754
[Full Text]
Samadfam, R., Xia, Q., Goltzman, D.
(2007). Pretreatment with Anticatabolic Agents Blunts But Does Not Eliminate the Skeletal Anabolic Response to Parathyroid Hormone in Oophorectomized Mice. Endocrinology
148: 2778-2787
[Abstract][Full Text]
Suliburk, J. W., Perrier, N. D.
(2007). Primary Hyperparathyroidism. The Oncologist
12: 644-653
[Abstract][Full Text]
Whyte, M. P., Mumm, S., Deal, C.
(2007). Adult Hypophosphatasia Treated with Teriparatide. J. Clin. Endocrinol. Metab.
92: 1203-1208
[Abstract][Full Text]
Greenspan, S. L., Bone, H. G., Ettinger, M. P., Hanley, D. A., Lindsay, R., Zanchetta, J. R., Blosch, C. M., Mathisen, A. L., Morris, S. A., Marriott, T. B., for the Treatment of Osteoporosis with Parathyroid,
(2007). Effect of Recombinant Human Parathyroid Hormone (1-84) on Vertebral Fracture and Bone Mineral Density in Postmenopausal Women with Osteoporosis: A Randomized Trial. ANN INTERN MED
146: 326-339
[Abstract][Full Text]
Antoniucci, D. M., Sellmeyer, D. E., Bilezikian, J. P., Palermo, L., Ensrud, K. E., Greenspan, S. L., Black, D. M.
(2007). Elevations in Serum and Urinary Calcium with Parathyroid Hormone (1-84) with and without Alendronate for Osteoporosis. J. Clin. Endocrinol. Metab.
92: 942-947
[Abstract][Full Text]
Serra, A. L., Savoca, R., Huber, A. R., Hepp, U., Delsignore, A., Hersberger, M., Wuthrich, R. P.
(2007). Effective control of persistent hyperparathyroidism with cinacalcet in renal allograft recipients. Nephrol Dial Transplant
22: 577-583
[Abstract][Full Text]
Poole, K. E S, Compston, J. E
(2006). Osteoporosis and its management. BMJ
333: 1251-1256
[Full Text]
Rey, A., Manen, D., Rizzoli, R., Caverzasio, J., Ferrari, S. L.
(2006). Proline-rich Motifs in the Parathyroid Hormone (PTH)/PTH-related Protein Receptor C Terminus Mediate Scaffolding of c-Src with beta-Arrestin2 for ERK1/2 Activation. J. Biol. Chem.
281: 38181-38188
[Abstract][Full Text]
Cummings, S. R.
(2006). A 55-Year-Old Woman With Osteopenia. JAMA
296: 2601-2610
[Abstract][Full Text]
Pazianas, M., Compher, C., Schiavone-Gatto, P., Kinosian, B. P.
(2006). Intestinal Failure-Associated Metabolic Bone Diseases and Response to Teriparatide. Nutr Clin Pract
21: 605-609
[Abstract][Full Text]
Jolette, J., Wilker, C. E., Smith, S. Y., Doyle, N., Hardisty, J. F., Metcalfe, A. J., Marriott, T. B., Fox, J., Wells, D. S.
(2006). Defining a Noncarcinogenic Dose of Recombinant Human Parathyroid Hormone 1-84 in a 2-Year Study in Fischer 344 Rats. Toxicol Pathol
34: 929-940
[Abstract][Full Text]
Lewiecki, E. M., Laster, A. J.
(2006). Clinical Applications of Vertebral Fracture Assessment by Dual-Energy X-Ray Absorptiometry. J. Clin. Endocrinol. Metab.
91: 4215-4222
[Abstract][Full Text]
Chung, D. J., Castro, C. H. M., Watkins, M., Stains, J. P., Chung, M. Y., Szejnfeld, V. L., Willecke, K., Theis, M., Civitelli, R.
(2006). Low peak bone mass and attenuated anabolic response to parathyroid hormone in mice with an osteoblast-specific deletion of connexin43. J. Cell Sci.
119: 4187-4198
[Abstract][Full Text]
Xue, Y., Karaplis, A. C., Hendy, G. N., Goltzman, D., Miao, D.
(2006). Exogenous 1,25-Dihydroxyvitamin D3 Exerts a Skeletal Anabolic Effect and Improves Mineral Ion Homeostasis in Mice that Are Homozygous for Both the 1{alpha}-Hydroxylase and Parathyroid Hormone Null Alleles. Endocrinology
147: 4801-4810
[Abstract][Full Text]
Turner, R. T., Lotinun, S., Hefferan, T. E., Morey-Holton, E.
(2006). Disuse in adult male rats attenuates the bone anabolic response to a therapeutic dose of parathyroid hormone. J. Appl. Physiol.
101: 881-886
[Abstract][Full Text]
Wildschut, H. I.J., Peters, T.J., Weiner, C. P.
(2006). Screening in women's health, with emphasis on fetal Down's syndrome, breast cancer and osteoporosis. Hum Reprod Update
12: 499-512
[Abstract][Full Text]
Finkelstein, J. S., Leder, B. Z., Burnett, S.-A. M., Wyland, J. J., Lee, H., de la Paz, A. V., Gibson, K., Neer, R. M.
(2006). Effects of Teriparatide, Alendronate, or Both on Bone Turnover in Osteoporotic Men. J. Clin. Endocrinol. Metab.
91: 2882-2887
[Abstract][Full Text]
Jakob, F., Marin, F., Martin-Mola, E., Torgerson, D., Fardellone, P., Adami, S., Thalassinos, N.C., Sykes, D., Melo-Gomes, J., Chinn, C., Nicholson, T., Cooper, C.
(2006). Characterization of patients with an inadequate clinical outcome from osteoporosis therapy: the Observational Study of Severe Osteoporosis (OSSO). QJM
99: 531-543
[Abstract][Full Text]
Hodsman, A., Papaioannou, A., Cranney, A.
(2006). Clinical practice guidelines for the use of parathyroid hormone in the treatment of osteoporosis.. CMAJ
175: 48-48
[Full Text]
Cranney, A., Papaioannou, A., Zytaruk, N., Hanley, D., Adachi, J., Goltzman, D., Murray, T., Hodsman, A., for the Clinical Guidelines Committee of Osteoporo,
(2006). Parathyroid hormone for the treatment of osteoporosis: a systematic review.. CMAJ
175: 52-59
[Abstract][Full Text]
Tsukiyama, K., Yamada, Y., Yamada, C., Harada, N., Kawasaki, Y., Ogura, M., Bessho, K., Li, M., Amizuka, N., Sato, M., Udagawa, N., Takahashi, N., Tanaka, K., Oiso, Y., Seino, Y.
(2006). Gastric Inhibitory Polypeptide as an Endogenous Factor Promoting New Bone Formation after Food Ingestion. Mol. Endocrinol.
20: 1644-1651
[Abstract][Full Text]
Mittelman, S. D., Hendy, G. N., Fefferman, R. A., Canaff, L., Mosesova, I., Cole, D. E. C., Burkett, L., Geffner, M. E.
(2006). A Hypocalcemic Child with a Novel Activating Mutation of the Calcium-Sensing Receptor Gene: Successful Treatment with Recombinant Human Parathyroid Hormone. J. Clin. Endocrinol. Metab.
91: 2474-2479
[Abstract][Full Text]
Pickard, B. W., Hodsman, A. B., Fraher, L. J., Watson, P. H.
(2006). Type 1 Parathyroid Hormone Receptor (PTH1R) Nuclear Trafficking: Association of PTH1R with Importin {alpha}1 and {beta}. Endocrinology
147: 3326-3332
[Abstract][Full Text]
Cockayne, S., Adamson, J., Lanham-New, S., Shearer, M. J., Gilbody, S., Torgerson, D. J.
(2006). Vitamin K and the Prevention of Fractures: Systematic Review and Meta-analysis of Randomized Controlled Trials.. Arch Intern Med
166: 1256-1261
[Abstract][Full Text]
Liu, H., Michaud, K., Nayak, S., Karpf, D. B., Owens, D. K., Garber, A. M.
(2006). The Cost-effectiveness of Therapy With Teriparatide and Alendronate in Women With Severe Osteoporosis.. Arch Intern Med
166: 1209-1217
[Abstract][Full Text]
Nayak, S., Olkin, I., Liu, H., Grabe, M., Gould, M. K., Allen, I. E., Owens, D. K., Bravata, D. M.
(2006). Meta-analysis: accuracy of quantitative ultrasound for identifying patients with osteoporosis.. ANN INTERN MED
144: 832-841
[Abstract][Full Text]
Sanchez, A. J., Aranda-Michel, J.
(2006). Liver Disease and Osteoporosis. Nutr Clin Pract
21: 273-278
[Abstract][Full Text]
Yakar, S., Bouxsein, M. L, Canalis, E., Sun, H., Glatt, V., Gundberg, C., Cohen, P., Hwang, D., Boisclair, Y., LeRoith, D., Rosen, C. J
(2006). The ternary IGF complex influences postnatal bone acquisition and the skeletal response to intermittent parathyroid hormone.. J Endocrinol
189: 289-299
[Abstract][Full Text]
Donahue, S. W., Galley, S. A., Vaughan, M. R., Patterson-Buckendahl, P., Demers, L. M., Vance, J. L., McGee, M. E.
(2006). Parathyroid hormone may maintain bone formation in hibernating black bears (Ursus americanus) to prevent disuse osteoporosis. J. Exp. Biol.
209: 1630-1638
[Abstract][Full Text]
PARTRIDGE, N. C., LI, X., QIN, L.
(2006). Understanding Parathyroid Hormone Action. Ann. N. Y. Acad. Sci.
1068: 187-193
[Abstract][Full Text]
MARTIN, T.J., QUINN, J.M.W., GILLESPIE, M.T., NG, K.W., KARSDAL, M.A., SIMS, N.A.
(2006). Mechanisms Involved in Skeletal Anabolic Therapies. Ann. N. Y. Acad. Sci.
1068: 458-470
[Abstract][Full Text]
Koo, W. W.K., Hockman, E. M., Dow, M.
(2006). Palm olein in the fat blend of infant formulas: effect on the intestinal absorption of calcium and fat, and bone mineralization.. J. Am. Coll. Nutr.
25: 117-122
[Abstract][Full Text]
Bauer, D. C., Garnero, P., Bilezikian, J. P., Greenspan, S. L., Ensrud, K. E., Rosen, C. J., Palermo, L., Black, D. M., for the PTH and Alendronate (PaTH) Research Group,
(2006). Short-Term Changes in Bone Turnover Markers and Bone Mineral Density Response to Parathyroid Hormone in Postmenopausal Women with Osteoporosis. J. Clin. Endocrinol. Metab.
91: 1370-1375
[Abstract][Full Text]
Young, N., Mikhalkevich, N., Yan, Y., Chen, D., Zheng, W.-p.
(2005). Differential Regulation of Osteoblast Activity by Th Cell Subsets Mediated by Parathyroid Hormone and IFN-{gamma}. J. Immunol.
175: 8287-8295
[Abstract][Full Text]
Potts, J. T
(2005). Parathyroid hormone: past and present. J Endocrinol
187: 311-325
[Abstract][Full Text]
Bellido, T., Ali, A. A., Gubrij, I., Plotkin, L. I., Fu, Q., O'Brien, C. A., Manolagas, S. C., Jilka, R. L.
(2005). Chronic Elevation of Parathyroid Hormone in Mice Reduces Expression of Sclerostin by Osteocytes: A Novel Mechanism for Hormonal Control of Osteoblastogenesis. Endocrinology
146: 4577-4583
[Abstract][Full Text]
Castro, M., Nikolaev, V. O., Palm, D., Lohse, M. J., Vilardaga, J.-P.
(2005). Turn-on switch in parathyroid hormone receptor by a two-step parathyroid hormone binding mechanism. Proc. Natl. Acad. Sci. USA
102: 16084-16089
[Abstract][Full Text]
Karlsson, M. K., Gerdhem, P., Ahlborg, H. G.
(2005). The prevention of osteoporotic fractures. J Bone Joint Surg Br
87-B: 1320-1327
[Full Text]
Black, D. M., Bilezikian, J. P., Ensrud, K. E., Greenspan, S. L., Palermo, L., Hue, T., Lang, T. F., McGowan, J. A., Rosen, C. J., the PaTH Study Investigators,
(2005). One Year of Alendronate after One Year of Parathyroid Hormone (1-84) for Osteoporosis. NEJM
353: 555-565
[Abstract][Full Text]
Cosman, F., Nieves, J., Zion, M., Woelfert, L., Luckey, M., Lindsay, R.
(2005). Daily and Cyclic Parathyroid Hormone in Women Receiving Alendronate. NEJM
353: 566-575
[Abstract][Full Text]
Rosen, C. J.
(2005). Postmenopausal Osteoporosis. NEJM
353: 595-603
[Full Text]
Vieth, R., Cole, D. E.C., Krege, J. H., Donley, D. W., Marcus, R., Licata, A. A.
(2005). Teriparatide, Osteoporosis, Calcium, and Vitamin D. NEJM
353: 634-635
[Full Text]
McClung, M. R., San Martin, J., Miller, P. D., Civitelli, R., Bandeira, F., Omizo, M., Donley, D. W., Dalsky, G. P., Eriksen, E. F.
(2005). Opposite Bone Remodeling Effects of Teriparatide and Alendronate in Increasing Bone Mass. Arch Intern Med
165: 1762-1768
[Abstract][Full Text]
Hodsman, A. B., Bauer, D. C., Dempster, D. W., Dian, L., Hanley, D. A., Harris, S. T., Kendler, D. L., McClung, M. R., Miller, P. D., Olszynski, W. P., Orwoll, E., Yuen, C. K.
(2005). Parathyroid Hormone and Teriparatide for the Treatment of Osteoporosis: A Review of the Evidence and Suggested Guidelines for Its Use. Endocr. Rev.
26: 688-703
[Abstract][Full Text]
Maimoun, L, Simar, D, Malatesta, D, Caillaud, C, Peruchon, E, Couret, I, Rossi, M, Mariano-Goulart, D
(2005). Response of bone metabolism related hormones to a single session of strenuous exercise in active elderly subjects. Br. J. Sports. Med.
39: 497-502
[Abstract][Full Text]
Paschalis, E. P., Glass, E. V., Donley, D. W., Eriksen, E. F.
(2005). Bone Mineral and Collagen Quality in Iliac Crest Biopsies of Patients Given Teriparatide: New Results from the Fracture Prevention Trial. J. Clin. Endocrinol. Metab.
90: 4644-4649
[Abstract][Full Text]
Raisz, L. G.
(2005). Screening for Osteoporosis. NEJM
353: 164-171
[Full Text]
Dobnig, H., Sipos, A., Jiang, Y., Fahrleitner-Pammer, A., Ste-Marie, L.-G., Gallagher, J. C., Pavo, I., Wang, J., Eriksen, E. F.
(2005). Early Changes in Biochemical Markers of Bone Formation Correlate with Improvements in Bone Structure during Teriparatide Therapy. J. Clin. Endocrinol. Metab.
90: 3970-3977
[Abstract][Full Text]
Barbier, J.-R., Gardella, T. J., Dean, T., MacLean, S., Potetinova, Z., Whitfield, J. F., Willick, G. E.
(2005). Backbone-methylated Analogues of the Principle Receptor Binding Region of Human Parathyroid Hormone: EVIDENCE FOR BINDING TO BOTH THE N-TERMINAL EXTRACELLULAR DOMAIN AND EXTRACELLULAR LOOP REGION. J. Biol. Chem.
280: 23771-23777
[Abstract][Full Text]
Fogelman, I., Blake, G. M
(2005). Strontium ranelate for the treatment of osteoporosis. BMJ
330: 1400-1401
[Full Text]
Liu, P.-Q., Tan, S., Mendel, M. C., Murrills, R. J., Bhat, B. M., Schlag, B., Samuel, R., Matteo, J. J., de la Rosa, R., Howes, K., Reik, A., Case, C. C., Bex, F. J., Young, K., Gregory, P. D.
(2005). Isogenic Human Cell Lines for Drug Discovery: Regulation of Target Gene Expression by Engineered Zinc-Finger Protein Transcription Factors. J Biomol Screen
10: 304-313
[Abstract]
Yamaguchi, M., Ogata, N., Shinoda, Y., Akune, T., Kamekura, S., Terauchi, Y., Kadowaki, T., Hoshi, K., Chung, U.-I., Nakamura, K., Kawaguchi, H.
(2005). Insulin Receptor Substrate-1 Is Required for Bone Anabolic Function of Parathyroid Hormone in Mice. Endocrinology
146: 2620-2628
[Abstract][Full Text]
Licata, A. A.
(2005). Osteoporosis, Teriparatide, and Dosing of Calcium and Vitamin D. NEJM
352: 1930-1931
[Full Text]
Strewler, G. J.
(2005). A 64-Year-Old Woman With Primary Hyperparathyroidism. JAMA
293: 1772-1779
[Full Text]
Alkhiary, Y. M., Gerstenfeld, L. C., Krall, E., Westmore, M., Sato, M., Mitlak, B. H., Einhorn, T. A.
(2005). Enhancement of Experimental Fracture-Healing by Systemic Administration of Recombinant Human Parathyroid Hormone (PTH 1-34). JBJS
87: 731-741
[Abstract][Full Text]
Previous
